tbuckley/cabot-search huggingface dataset:
OP0064 Joint EULAR/ERA-EDTA recommendations for the management of adult and pediatric lupus nephritis
Authors: G. Bertsias, M. Tektonidou, Z. Amoura, M. Aringer, I. Bajema, J. Berden, J. Boletis, R. Cervera, T. Dörner, A. Doria, F. Ferrario, J. Flöge, F. Houssiau, J.P. Ioannidis, D. Isenberg, C.G. Kallenberg, L. Lightstone, S. Marks, A. Martini, G. Moroni, I. Neumann, P. Niaudet, M. Praga, M. Schneider, V. Tesar, C. Vasconcelos, R. van Vollenhoven, E. Zakharova, M. Haubitz, C. Gordon, D. Jayne, D. Boumpas
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> There is increasing evidence from clinical trials on which to base a rational approach to the care of lupus nephritis (LN). <h3>Objectives</h3> To develop recommendations for the management of LN. <h3>Methods</h3> Questions were compiled using a modified Delphi technique. A systematic PubMed search was performed, and evidence-based and expert-opinion approach was followed to prepare recommendations. <h3>Results</h3> No clinical, serologic or laboratory tests can accurately predict renal biopsy findings in SLE; any sign of renal involvement, especially proteinuria &gt;0.5 g/24-hr, should be an indication for biopsy. Assessment should include glomerular changes, activity and chronicity indices, tubulointerstitial lesions, and vascular lesions. Because of more favourable efficacy/toxicity ratio, for most patients with ISN/RPS2003 Class III<sub>A</sub> or <sub>A/C</sub> and Class IV<sub>A</sub> or <sub>A/C</sub> (±V) LN, mycophenolate mofetil (MMF) or low-dose intravenous cyclophosphamide (CY) in combination with glucocorticoids is recommended. Induction regimens should be combined initially with three daily pulses of IV methylprednisolone, followed by oral prednisolone 0.5 mg/kg/day. In patients with adverse clinical or histological features, CY can also be prescribed monthly at higher doses (0.75-1g/m<sup>2</sup>) for 6 months or orally for 3 months. For pure class V disease with nephrotic-range proteinuria, MMF in combination with oral prednisolone may be used initially. In patients responding to initial therapy (≥50% reduction in proteinuria and stable/improved GFR) within 6-12 months, maintenance immunosuppression is recommended with MMF or azathioprine for at least 3 years. For MMF or CY failures, we recommend switching to the other or rituximab. Pregnancy should be planned in stable patients with inactive lupus and serum creatinine &lt;2 mg/dL. The intensity of treatment should not be reduced in anticipation of pregnancy. Nephritis is more frequent at presentation in children with SLE and its diagnosis, management, and monitoring is similar to that in adults. <h3>Conclusions</h3> Recommendations for LN were developed using an evidence-based approach followed by expert consensus. <h3>Disclosure of Interest</h3> None Declared
Idiotypic IgA Nephropathy in Patients with Human Immunodeficiency Virus Infection
Authors: Paul L. Kimmel, Terry M. Phillips, Andrea Ferreira-Centeno, Tunde Farkas-Szallasi, A. Andrew Abraham, Carleton T. Garrett
Journal: New England Journal of Medicine (1992)

SEVERAL renal syndromes have been described in patients with human immunodeficiency virus (HIV) infection. The most common renal abnormality is focal segmental glomerulosclerosis,1 2 3 but some patients have evidence of immune-complex nephropathy,1 2 3 including membranoproliferative and diffuse proliferative glomerulonephritis,4 membranous nephropathy,5 and IgA nephropathy.6 , 7 HIV-related antigen–antibody circulating immune complexes have been demonstrated in patients with HIV infection,8 9 10 11 12 13 but not in renal tissue from patients with both the infection and renal disease; therefore, the importance of the circulating complexes is unknown. Although the pathogenesis of IgA nephropathy in patients with HIV infection6 , 7 is unknown, genetic factors or immune-complex mechanisms may be involved.14 , 15 Idiotypes, . . .
Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada’s Sentinel Physician Surveillance Network, January 2015
Authors: D M Skowronski, C Chambers, S Sabaiduc, G De Serres, J A Dickinson, A L Winter, S J Drews, K Fonseca, H Charest, J B Gubbay, M Petric, M Krajden, T L Kwindt, C Martineau, A Eshaghi, N Bastien, Y Li
Journal: Eurosurveillance (2015)

Binary file ES_Abstracts_Final_ECDC.txt matches
Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic Leukemia
Authors: John H. Kersey, Daniel Weisdorf, Mark E. Nesbit, Tucker W. LeBien, William G. Woods, Philip B. McGlave, Tae Kim, Daniel A. Vallera, Anne I. Goldman, Bruce Bostrom, David Hurd, Norma K.C. Ramsay
Journal: New England Journal of Medicine (1987)

Chemoradiotherapy and transplantation of bone marrow from matched sibling donors have been useful for the treatment of acute lymphoblastic leukemia in patients with a poor prognosis but are not available to some two thirds of patients who do not have a matched allogeneic donor. We undertook this study to compare autologous and allogeneic marrow transplantation in the treatment of such cases. We treated 91 patients with high-dose chemoradiotherapy and followed them for 1.4 to 5 years. Forty-six patients with an HLA-matched donor received allogeneic marrow, and 45 patients without a matched donor received their own marrow taken during remission and purged of leukemic cells with use of monoclonal antibodies. Bone marrow engraftment occurred earlier in patients who received autologous marrow. Recipients of autologous marrow had shorter hospital courses, with significantly fewer peritransplantation deaths than recipients of allogeneic marrow. Post-transplantation relapse of leukemia was the most frequent cause of treatment failure; relapses occurred in an estimated 37 percent of patients with allogeneic grafts in whom graft-versus-host disease developed, 75 percent of patients with allogeneic grafts in whom graft-versus-host disease did not develop, and 79 percent of patients who received autologous grafts. The interval before relapse was significantly shorter in the autologous-marrow group than in the allogeneic-marrow group. Recipients of autologous and allogeneic marrow whose first pretransplantation remissions were short (less than 18 months) had eventual outcomes similar to those whose first remissions were longer than 18 months. Patients with a first remission lasting less than 18 months had an outcome better than that expected with chemotherapy alone. The fractions of "cured" patients were estimated to be 20 percent in the autologous-marrow group and 27 percent in the allogeneic-marrow group — not a significant difference, but because of the limited statistical power of the study, the question of long-term disease-free survival must still be considered open. (N Engl J Med 1987; 317:461–7.)
Use of Various Diagnostic Methods in a Patient With Gaucher Disease Type I
Authors: JAMSHID FARAHATI, GUIDO TRENN, VERA JOHN-MIKOLAJEWSKI, CHRISTINA ZANDER, GREGORY M. PASTORES, JOACHIM SCIUK, CHRISTOPH REINERS
Journal: Clinical Nuclear Medicine (1996)

A series of plain radiographs, bone scans, bone marrow scans, and MRIs is reported in a patient with Gaucher disease type I, in whom two episodes of acute bone crisis developed during a 6-year period of follow-up. Acute bone crisis and global indolent bone marrow displacement could both be assessed by bone marrow scintigraphy, whereas MRI could better clarify the corticomedullary alteration after bone infarction. Thus, MRI and bone marrow scintigraphy could be used as complementary imaging methods in the management of patients with Gaucher disease.
SC-37 * THE ROLE OF NG2 EXPRESSING PROGENITOR CELLS IN DIFFUSE INTRINSIC PONTINE GLIOMA
Authors: S. Yadavilli, O. J. Becher, M. Kambhampati, R. J. Packer, J. Nazarian
Journal: Neuro-Oncology (2014)

Pediatric diffuse intrinsic pontine glioma (DIPG) is one of the most difficult cancers to treat. pLys27Met (K27M) driver mutation in the H3F3A (H3.3) and HIST1H3B (H3.1) genes of histone are correlated with a subgroup of DIPGs. Other genomic aberrations include p53 mutations and amplification of signaling pathways including PDGFRα. We have recently reported the involvement of Hedgehog (Hh) pathway in a subset of DIPGs. Modulation of Hh and tyrosine kinase receptors may alter the self-renewal properties of cancer stem cells (CSC). NG2 Proteoglycan positive cells that co-express PDGFRα and Olig-2 are present in adult gliomas, where NG2 contributes to the neoplastic transformation of glioma cells. We examined NG2 expression in frozen brainstem specimens of DIPGs and observed significant NG2 expression in DIPGs [10 of 14 (71 %), fold change = 33, p < 0.05)] as compared to the adjacent normal tissue. NG2 expression was associated with histone 3 K27M mutation [8 of 10 (80 %)]. Two mechanisms of NG2 regulation in DIPG were identified: i) histone 3 binds to NG2 promoter, and ii) miR 129-2 negatively regulates NG2. We detected downregulation of miR129-2 in 85.7% (6 of 7) of DIPG tumors compared to normal tissue (FC = -30.79, n = 7 pairs). We also found overall hypermethylation at 8 CpG loci corresponding to the miR129-2 promoter. NG2 knockdown in vitro (shRNA, miR129-2 or demethylating drugs) retards cellular migration. Luciferase assay in primary mouse glioma cells co-transfected with 3'UTR of NG2 and miR129-2 revealed regulation of NG2 by miR129-2. This was further confirmed in vivo by injection of NG2-dsRed transgenic mice with mir129-2 lentivirus. Orthotopic injection of NG2+ cells results in rapid tumor formation while NG2-KD cells fail to form tumors. Our study offers a potential model for the expansion of tumor stem cells and their self-renewal properties in DIPGs.
Abstract 4216: Protein kinase C ≤ overexpression is associated with loss of membrane-associated E-cadherin and β-catenin in T47D xenograft breast tumors
Authors: Bethany E. Perez White, Huiping Zhao, Madhuchhanda Kundu, Mary Ellen Molloy, Debra A. Tonetti
Journal: Cancer Research (2012)

Abstract Expression of protein kinase C ≤ (PKC∈) has been shown to be a clinically relevant indicator of tamoxifen response, recurrence and overall survival in breast cancer (Tonetti, 2003; Assender 2007). To study this association, we developed a model of PKC∈-overexpressing breast cancer by stable transfection of the prkca gene into T47D breast cancer cells (T47D/PKC∈, Tonetti, 2000). We have shown that PKC∈ induces a hormone-independent, tamoxifen-resistant phenotype in vitro and in vivo (Chisamore, 2001). This model is further characterized in vitro by increased migratory and invasive capability, expression of mesenchymal markers and reduced expression of adherens junctions and epithelial proteins (Perez White, AACR 2011). β-Catenin and E-cadherin are components of adherens junctions in normal epithelia and loss of E-cadherin is associated with worse outcome in breast cancer (Prat, 2010). Further, the reduction or cytoplasmic relocalization of β-catenin has been associated with poor prognosis (Lopez-Knowles, 2010; Dolled-Filhart, 2006) though the processes upstream or downstream of these changes are not well characterized in breast cancer. Therefore we hypothesized that xenograft tumors derived from T47D/PKC∈ cells would have loss of membrane-associated β-catenin and E-cadherin. Immunofluorescence staining showed cytoplasmic localization of β-catenin and E-cadherin in T47D/PKC∈ tumors in sharp contrast to membrane association in T47D/neo (vector control) tumors. Western blot showed reduction in the level of E-cadherin in T47D/PKC∈ tumor samples but no change in the level of β-catenin compared to T47D/neo tumors. Based on this, we next wanted evaluate the β-catenin degradation pathway mediated by glycogen synthase kinase-3β (GSK-3β). Cellular extracts show an increase in the levels of the serine 9 inhibitory phosphorylation of GSK-3β in T47D/PKC∈ cells but no increase in total protein compared to T47D/neo cells. Treatment with the proteasomal inhibitor MG132 (10 μM) for 2 h did not increase the levels of β-catenin in vitro in T47D/PKC∈ cells. Current data indicate a correlation between PKC∈ expression and loss of membrane-associated β-catenin and E-cadherin. Further, β-catenin is stabilized in the cytoplasm of T47D/PKC∈ cells possibly allowing for nuclear localization and downstream gene transcription. Taken together with previous data, PKC∈ correlates with markers of poor outcome in addition to hormone-independence and tamoxifen-resistance suggesting that PKC∈ may play a central role in breast cancer progression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4216. doi:1538-7445.AM2012-4216
Abstract P5-10-22: Dose Dense Adjuvant Chemotherapy in Breast Cancer Patients with Five or More Nodes Involved: Results of a French Cohort with Long Term Follow-Up
Authors: CC Cuvier, FF Hocine, AS Hamy, SS Giacchetti, AA de Roquancourt, PP Charveriat, MM Marty, JJ Lehmann-Che, RR Porcher, MM. Espie
Journal: Cancer Research (2010)

Abstract Introduction: Axillary node involvement remains the most important prognosis factor in breast cancer patients. In those with ≥ positive nodes, 5-year overall survival rates range from 47% to 22% and 5-year recurrence rate from 54% to 82%. Several trials have studied the impact of dose dense chemotherapy in node-positive breast cancer. Some have shown a significant improvement in relapse-free survival and even overall survival. However the power of these studies is often insufficient to conclude and the follow up is often short. Objective: To provide safety and long term efficacy data of a dose dense chemotherapy regimen used in Saint Louis Hospital for patients with ≥5 positive nodes. Materials and methods: Beetween 1990 and 2003, all patients with ≥5 positive nodes were treated with adjuvant dose dense chemotherapy: 6 cycles of epirubicin 75mg/m2, cyclophosphamide 1200mg/m2 q2w followed by 3 cycles of conventional chemotherapy. No prophylactic G-CSF was given.All patients received adjuvant radiation therapy. Of 95 patients with HR positive tumors,44 received adjuvant tamoxifene therapy after completion of chemotherapy. Patients were followed by clinical and laboratory examinations every 4 months for 3 years then every 6 months for 2 years and every year thereafter. A mammogram was performed each year. Results: Patients characteristics: Patients characteristics at inclusion. Figures are median (range) or no. (%). (Her2 expression will be presented at the meeting.) Median time between surgery and chemotherapy was 30 days (9-91).Grade 3 or 4 toxicities were mainly: neutropenia (89%) gastro-intestinal toxicity(30%) febrile neutropenia 24% cardiac toxicity 2.6% toxic death:1 pt. Median follow-up since the initiation of chemotherapy:10.9 years. Median survival:11.3 years (95% CI 9.4-∞) and median disease-free survival 6.1 years (95% CI 4.6- 8).5, 10 and 15 overall survival rates were 76%, 56% and 41%respectively and disease-free survival were 54%, 37% and 34% respectively. Conclusion: In this very high risk selected population, our dose-dense chemotherapy regimen exhibits an exceptionnaly high 10-year survival rate. A sequential association with taxanes should be studied. Figure available in online version. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-10-22.
Ocular Malignant Melanoma Detected With Tc-99m MIBI and Tc-99m HMPAO
Authors: İSMET SARIKAYA, ERKAN İBİŞ, İLHAN GÜNALP, GÜLSEREN ARAS
Journal: Clinical Nuclear Medicine (1999)

Ocular melanoma has been studied with various radionuclides, but there is no report of ocular melanoma showing Tc-99m MIBI and Tc-99m HMPAO uptake. Because Tc-99m HMPAO contains amine radicals in its structure, it can bind amine receptors on melanoma cells if present. We describe two patients with primary ocular melanoma showing Tc-99m MIBI and Tc-99m HMPAO uptake in the primary tumor.
Abstract 1458: Orthotopic imageable peritoneal carcinomatosis GFP nude mouse model of human esophageal cancer
Authors: Stephanie J. Gros, Thorsten Dohrmann, Jussuf T. Kaifi, Michael Bouvet, Robert M. Hoffman, Jakob R. Izbicki
Journal: Cancer Research (2010)

Abstract The aim of this study was to establish an imageable orthotopic GFP-expressing nude-mouse model of human esophageal cancer peritoneal carcinomatosis. Nude mice were orthotopically injected in the abdominal esophagus with stably transfected GFP- PT1590 human esophageal cancer cells. Tumor progression was visualized by fluorescence imaging. Fifty percent of the animals developed extensive peritoneal spread without a distinct primary tumor at the injection site. Continuous and metastatic spread to liver, lung, and lymph node was also observed. Fluorescence imaging enabled rapid and specific visualization of tumor progression without anaesthesia. Intraperitoneal and metastatic tumor spread of GFP-PT1590 esophageal carcinoma demonstrated a highly aggressive but heterogenous behaviour. Although injection of the esophageal carcinoma cell line PT1590-GFP did not lead to primary esophageal tumor development at the site of injection, 50% of the mice developed extensive peritoneal spread as well as lymph node and organ metastasis. The orthotopic cell injection model resulting in peritoneal carcinomatosis of esophageal adenocarcinoma, which can be visualized in real time using fluorescence imaging, will be a valuable tool for the study of esophageal cancer metastasis and its treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1458.
AB0280 Audio versus Visual: Does IT Matter How You Obtain Patient Global Score for DAS-28 Calculation?
Authors: O. Savanovic-Abel, R. Mascarenhas
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The DAS-28 is the most commonly used score to assess rheumatoid disease activity. It is a composite score based on four variables: tender joint count, swollen joint count, acute phase response and a patient global health assessment on a visual analogue score (VAS). A survey of rheumatologists in our region demonstrated that in clinical practice patients are often asked to score this verbally (audio scale 0-100) as a surrogate to the VAS. The assumption is that there would be no difference between the two values but is that truly the case? <h3>Objectives</h3> The aim of this study was to investigate correlation between DAS-28 values calculated with a VAS and DAS-28 derived from an audio score. <h3>Methods</h3> Patients with rheumatoid arthritis attending for regular follow-up were asked to assess their global health on a VAS and also to score their health verbally (audio score). One of the questions was asked at the start of the consultation and another at the end. The order of the questions varied between the patients. The individual values of the VAS and audio scores were then used to calculate two separate DAS-28 results for each patient. The DAS-28 results were then compared with each other to see if there was any meaningful difference between values calculated depending on the method used to assess global health. If there was a difference we proceeded to see if this could have affected clinical management. This was conducted across two hospitals. <h3>Results</h3> Data was obtained from 59 patients. In four patients (6.78%) the two DAS-28 values differed depending on the global health measurement. In three (5.08%) of those patients standard DAS-28 indicated low disease activity whereas audio DAS-28 indicated remission. In one patient (1.69%) the difference of 0.17 between the two DAS-28 values corresponded to the difference between moderate disease activity (standard DAS-28) and high disease activity (audio DAS-28). However the difference between the scores did not affect clinical management in any of these patients. The difference between the two sets of DAS-28 values in our cohort of patients was not statistically significant (p-value =0.25). <h3>Conclusions</h3> In our study there is no significant difference in DAS-28 values derived from the standard validated VAS approach as compared to those from an audio score. This is reassuring and supports the use of the audio score as a convenient alternative to the VAS in routine clinical practice. However, the values that patients give for an audio score tend to be round numbers so one should consider reassessment with VAS if the initial audio derived DAS-28 result is borderline across disease activity states. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2004
The Relation between Health Insurance Coverage and Clinical Outcomes among Women with Breast Cancer
Authors: John Z. Ayanian, Betsy A. Kohler, Toshi Abe, Arnold M. Epstein
Journal: New England Journal of Medicine (1993)

Women without private health insurance are less likely than privately insured women to be screened for breast cancer, and their treatment may differ after cancer is diagnosed. In this study we addressed two related questions: Do uninsured patients and those covered by Medicaid have more advanced breast cancer than privately insured patients when the disease is initially diagnosed? And, for each stage of disease, do uninsured patients and patients covered by Medicaid die sooner after breast cancer is diagnosed than privately insured patients?
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Authors: Claire Bombardier, Loren Laine, Alise Reicin, Deborah Shapiro, Ruben Burgos-Vargas, Barry Davis, Richard Day, Marcos Bosi Ferraz, Christopher J. Hawkey, Marc C. Hochberg, Tore K. Kvien, Thomas J. Schnitzer
Journal: New England Journal of Medicine (2000)

Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who are taking nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis.